Key result
Lower respiratory COVID-19 linked to ~3-fold higher risk of prolonged symptoms in elite athletes.
Why the study?
The study was conducted to report the COVID-19 illness pattern, symptom duration, and time loss in UK elite athletes.
Does a lower respiratory presentation predict prolonged symptom duration and delayed return to sport in elite athletes with COVID-19?
Observational (n=147)
Yes
Does a lower respiratory presentation predict prolonged symptom duration and delayed return to sport in elite athletes with COVID-19?
COVID-19 in elite athletes is generally mild and self-limiting, but a lower respiratory tract presentation predicts a higher risk of prolonged symptoms and a delayed return to full athletic participation.
May warrant closer monitoring of elite athletes with lower respiratory COVID-19; leaves open optimal return-to-sport strategies pending prospective data.
OBJECTIVES: To report COVID-19 illness pattern, symptom duration and time loss in UK elite athletes. METHODS: Observational, clinical and database review of athletes with symptomatic COVID-19 illness managed within the UK Sports Institutes. Athletes were classified as confirmed (positive SARS-CoV-2 PCR or antibody tests) or probable (consistent clinical features) COVID-19. Clinical presentation was characterised by the predominant symptom focus (eg, upper or lower respiratory illness). Time loss was defined as days unavailable for full sport participation and comparison was made with a 2016-2019 respiratory illness dataset from the same surveillance system. RESULTS: Between 24 February 2020 and 18 January 2021, 147 athletes (25 Paralympic (17%)) with mean (SD) age 24.7 (5.2) years, 37% female, were diagnosed with COVID-19 (76 probable, 71 confirmed). Fatigue was the most prevalent symptom (57%), followed by dry cough (50%) and headache (46%). The median (IQR) symptom duration was 10 (6-17) days but 14% reported symptoms >28 days. Median time loss was 18 (12-30) days, with 27% not fully available >28 days from initial date of infection. This was greater than our historical non-COVID respiratory illness comparator; 6 days, 0-7 days (p<0.001) and 4% unavailable at 28 days. A lower respiratory phenotype (ie, including dyspnoea±chest pain±cough±fever) was present in 18% and associated with a higher relative risk of prolonged symptoms risk ratio 3.0 (95% CI: 1.4 to 6.5) and time loss 2.1 (95% CI: 1.2 to 3.5). CONCLUSIONS: In this cohort, COVID-19 largely resulted in a mild, self-limiting illness. The presence of lower respiratory tract features was associated with prolonged illness and a delayed return to sport.
No takes yet. Share an insight, caveat, or question.
Hull et al. (2021) conducted an observational in COVID-19 (n=147). Lower respiratory phenotype vs. Upper respiratory or other non-lower respiratory presentation was evaluated on Prolonged symptoms (>28 days) (risk ratio 3.0, 95% CI 1.4 to 6.5, p=0.011). In elite athletes, a lower respiratory COVID-19 presentation was associated with a 3.0-fold higher risk of prolonged symptoms lasting over 28 days compared to other presentations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: